Immunohistochemistry of ibrutinib treated xenografts confirmed that treatment response reflects mutational status (Figure 3 ) with a strong trend towards an increase in apoptosis in ibrutinib treated OCI-LY10 xenografts.
← all excerpts
Functional imaging in combination with mutation status aids prediction of response to inhibiting B-cell receptor signaling in lymphoma.
1
—
—